BRAF is more commonly mutated in younger patients with more nevi and sun exposure and those with superficial-spreading melanoma (SSM) (up to 50%) and is now targeted with BRAF + MEK small molecular inhibitors as a front-line treatment [16,17,18]. This evidence concerns the gene MAP2K7 and superficial spreading melanoma.